Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor Dynamics.

IF 2.2 4区 数学 Q2 BIOLOGY
Kit Gallagher, Maximilian A R Strobl, Alexander R A Anderson, Philip K Maini
{"title":"Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor Dynamics.","authors":"Kit Gallagher, Maximilian A R Strobl, Alexander R A Anderson, Philip K Maini","doi":"10.1007/s11538-025-01525-y","DOIUrl":null,"url":null,"abstract":"<p><p>Adaptive therapy (AT) protocols have been introduced to combat drug resistance in cancer, and are characterized by breaks from maximum tolerated dose treatment (the current standard of care in most clinical settings). These breaks are scheduled to maintain tolerably high levels of tumor burden, employing competitive suppression of treatment-resistant sub-populations by treatment-sensitive sub-populations. AT has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate-resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma, with initial clinical results suggesting that it can offer significant extensions in the time to progression over the standard of care. Prior AT protocols apply drug treatment when the tumor is within a specific size window, typically determined by the initial tumor size. However, this approach may be sub-optimal as it does not account for variation in tumor dynamics between patients, resulting in significant heterogeneity in patient outcomes. Mathematical modeling and analysis have been proposed to optimize adaptive protocols, but they do not account for clinical restrictions, most notably the discrete time intervals between the clinical appointments where a patient's tumor burden is measured and their treatment schedule is re-evaluated. We present a general framework for deriving optimal treatment protocols that account for these discrete time intervals, and derive optimal schedules for several models to avoid model-specific personalization. We identify a trade-off between the frequency of patient monitoring and the time to progression attainable, and propose an AT protocol that determines drug dosing based on a patient-specific threshold for tumor size. Finally, we identify a subset of patients with qualitatively different dynamics that instead require a novel AT protocol based on a threshold that changes over the course of treatment.</p>","PeriodicalId":9372,"journal":{"name":"Bulletin of Mathematical Biology","volume":"87 10","pages":"146"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417256/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Mathematical Biology","FirstCategoryId":"100","ListUrlMain":"https://doi.org/10.1007/s11538-025-01525-y","RegionNum":4,"RegionCategory":"数学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Adaptive therapy (AT) protocols have been introduced to combat drug resistance in cancer, and are characterized by breaks from maximum tolerated dose treatment (the current standard of care in most clinical settings). These breaks are scheduled to maintain tolerably high levels of tumor burden, employing competitive suppression of treatment-resistant sub-populations by treatment-sensitive sub-populations. AT has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate-resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma, with initial clinical results suggesting that it can offer significant extensions in the time to progression over the standard of care. Prior AT protocols apply drug treatment when the tumor is within a specific size window, typically determined by the initial tumor size. However, this approach may be sub-optimal as it does not account for variation in tumor dynamics between patients, resulting in significant heterogeneity in patient outcomes. Mathematical modeling and analysis have been proposed to optimize adaptive protocols, but they do not account for clinical restrictions, most notably the discrete time intervals between the clinical appointments where a patient's tumor burden is measured and their treatment schedule is re-evaluated. We present a general framework for deriving optimal treatment protocols that account for these discrete time intervals, and derive optimal schedules for several models to avoid model-specific personalization. We identify a trade-off between the frequency of patient monitoring and the time to progression attainable, and propose an AT protocol that determines drug dosing based on a patient-specific threshold for tumor size. Finally, we identify a subset of patients with qualitatively different dynamics that instead require a novel AT protocol based on a threshold that changes over the course of treatment.

Abstract Image

Abstract Image

Abstract Image

适应性治疗的最佳治疗时机:将模型与肿瘤动力学相匹配。
适应性治疗(AT)方案已被引入对抗癌症耐药性,其特点是突破最大耐受剂量治疗(目前大多数临床环境中的护理标准)。这些中断计划维持可容忍的高水平肿瘤负荷,采用治疗敏感亚群对治疗耐药亚群的竞争性抑制。AT已被整合到几个正在进行或计划中的临床试验中,包括治疗转移性去势抵抗性前列腺癌、卵巢癌和braf突变黑色素瘤,初步临床结果表明,与标准治疗相比,它可以显著延长进展时间。先前的AT方案在肿瘤处于特定大小窗口时应用药物治疗,通常由初始肿瘤大小决定。然而,这种方法可能不是最优的,因为它没有考虑到患者之间肿瘤动力学的变化,导致患者结果的显著异质性。数学建模和分析已经提出了优化适应性方案,但它们没有考虑到临床限制,最明显的是临床预约之间的离散时间间隔,其中患者的肿瘤负担被测量和他们的治疗计划被重新评估。我们提出了一个通用框架,用于推导考虑这些离散时间间隔的最佳治疗方案,并推导出几个模型的最佳时间表,以避免模型特定的个性化。我们确定了患者监测频率和可实现的进展时间之间的权衡,并提出了一种基于患者肿瘤大小特异性阈值确定药物剂量的AT方案。最后,我们确定了一组具有不同动力学性质的患者,他们需要一种基于治疗过程中阈值变化的新型AT方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.90
自引率
8.60%
发文量
123
审稿时长
7.5 months
期刊介绍: The Bulletin of Mathematical Biology, the official journal of the Society for Mathematical Biology, disseminates original research findings and other information relevant to the interface of biology and the mathematical sciences. Contributions should have relevance to both fields. In order to accommodate the broad scope of new developments, the journal accepts a variety of contributions, including: Original research articles focused on new biological insights gained with the help of tools from the mathematical sciences or new mathematical tools and methods with demonstrated applicability to biological investigations Research in mathematical biology education Reviews Commentaries Perspectives, and contributions that discuss issues important to the profession All contributions are peer-reviewed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信